Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesutoclax + orelabrutinib
- Development stage
- Phase 3
- Lead developer
- Innocare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mesutoclax + orelabrutinib is an all-oral, chemo-free combination regimen being developed by InnoCare for the treatment of various B-cell malignancies. The combination consists of mesutoclax (ICP-248), a novel, highly selective oral B-cell lymphoma 2 (BCL2) inhibitor, and orelabrutinib (ICP-022), an approved selective Bruton's tyrosine kinase (BTK) inhibitor. By targeting both BCL2 and BTK, the regimen simultaneously inhibits two complementary survival pathways in B-cell malignancies to restore apoptosis and block B-cell receptor signaling. The combination is currently in Phase III clinical development for first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed/refractory mantle cell lymphoma (MCL), and has received Breakthrough Therapy Designation in China for relapsed/refractory marginal zone lymphoma (MZL).
- Other names
- ICP-248 + ICP-022ICP-248 + orelabrutinibmesutoclax + ICP-022orelabrutinib + ICP-248orelabrutinib + mesutoclax
02
Targets
BCL-2 (BCL-2 family)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on mesutoclax + orelabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesutoclax + orelabrutinib.